查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994096

導管溶栓裝置市場：依產品類型、臨床適應症、最終用戶及病患年齡層別分類－2026年至2032年全球市場預測

Catheter-Directed Thrombolysis Devices Market by Product Type, Clinical Indication, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，導管導引溶栓裝置市場價值將達到 4.8237 億美元，到 2026 年將成長至 5.116 億美元，到 2032 年將達到 6.9582 億美元，複合年成長率為 5.37%。

主要市場統計數據
基準年 2025 4.8237億美元
預計年份：2026年 5.116億美元
預測年份 2032 6.9582億美元
複合年成長率 (%) 5.37%

為不斷發展的臨床、營運和商業性趨勢制定清晰權威的框架，定義導管引導溶栓治療的引入和策略重點。

導管導引溶栓治療作為急性血管閉塞的關鍵治療方法，在器械設計、影像整合和手術流程最佳化等方面的進步推動下不斷發展。本執行摘要整合了影響該領域的關鍵臨床、商業性和監管趨勢，重點關注器械創新、不斷變化的醫療服務格局以及醫療服務提供者和製造商必須應對的營運要求。臨床醫師越來越傾向於採用標靶治療，以最大限度地提高溶栓效果，同時最大限度地減少溶栓藥物的全身暴露，這進一步凸顯了器械性能和輸送精準度的重要性。

整合影像、分散式護理路徑和策略夥伴關係如何重塑導管引導溶栓的設備設計、臨床工作流程和競爭優勢。

導管溶栓治療領域正經歷一場變革，這場變革不僅體現在設備升級上，更涵蓋了醫療服務模式、數位整合以及以價值為基礎的採購。其中一個主要轉變是影像、設備控制和手術分析的日益融合。這種更精準的整合使得溶栓藥物的輸送更加精準，並能即時評估再灌注情況，進而縮短手術時間，減少後續介入。因此，封閉回路型手術支援和資料收集在技術藍圖中的重要性日益凸顯，它們將為臨床決策和與支付方的互動提供資訊支援。

到 2025 年，關稅主導的供應鏈變化將迫使製造商重組其生產、採購和商業策略，以保護利潤率和市場進入。

截至2025年，美國近期一系列關稅政策的累積影響已經改變了進入導管導引溶栓治療市場的醫療設備製造商的供應鏈計算和策略採購策略。關稅提高了某些進口零件和成品的接收成本，促使許多供應商重新評估其採購地點，並加快對近岸外包和國內生產的投資。採購團隊目前正在權衡單位成本、前置作業時間容忍度和法規遵循之間的利弊，並擴大選擇多供應商策略來降低單一供應商的風險。

細分市場的效能要求和部署路徑，結合產品架構和醫療保健環境，揭示了它們如何決定臨床採用和商業性策略。

對產品和終端用戶細分的深入了解揭示了整個導管引導溶栓治療生態系統中差異化性能的促進因素和推廣應用障礙。根據產品類型，市場動態在輸注導管（包括持續輸注和脈衝輸注）、機械導管亞型（包括抽吸導管、溶栓導管和旋轉導管）以及超音波輔助導管（分為增強型超音波和標準型超音波）等類別中存在差異。每類產品都有其獨特的臨床應用情境和採購考量。輸注系統強調可控的稀釋劑輸送和導管留置特性。機械裝置需要在手術速度和栓塞風險之間進行權衡，以減少稀釋劑暴露。超音波輔助平台承諾更快地破壞血栓，補償是系統複雜性增加和訓練要求提高。

區域監管複雜性、支付方多樣性和不斷擴大的產能將如何影響美洲、歐洲、中東和非洲以及亞太地區的差異化打入市場策略？

區域趨勢對醫療設備的研發重點、監管策略和商業化部署有顯著影響，美洲、歐洲、中東和非洲（EMEA）以及亞太地區各自面臨不同的機會和挑戰。在美洲，完善的醫院網路、成熟的介入治療專家群體以及微創療法的快速普及，都為先進溶栓平台的早期應用提供了支持。然而，由於支付方報銷政策的差異以及對基於價值的合約日益重視，製造商需要提供強力的臨床和衛生經濟學證據，才能在主要醫院系統中獲得優先地位。

為什麼成功的公司要將平台級創新、證據產生和整合服務結合，以在溶栓治療領域建立永續的競爭優勢？

在導管導引溶栓治療領域，各公司之間的競爭格局日益呈現臨床差異化、系統層級整合和策略夥伴關係三者融合的趨勢。領先的研發公司正從提供單一導管產品轉向提供包含影像整合、手術分析和服務包的“生態系統策略”，旨在縮短學習曲線並改善治療效果。這項轉變進一步凸顯了廣泛的臨床數據、多中心真實世界數據以及支持強化培訓計畫的能力的重要性，這些計畫有助於降低醫療系統部署風險。

為高階主管提供可操作的、高優先順序的行動方案，透過互通性、彈性供應鏈和有針對性的證據生成，將技術差異化轉化為商業性規模。

產業領導者應推動一系列合作舉措，將設備層面的優勢轉化為永續的商業性成果。首先，應優先考慮互通性的產品架構，以實現與影像和數據系統的快速整合，從而簡化流程並促進治療效果的評估。投資模組化平台可減輕現有客戶的升級負擔，並透過耗材和服務合約創造持續的商機。其次，應協調臨床營運、法規遵循和報銷團隊，為重點細分市場和地區制定有針對性的證據包。能夠證明臨床獲益和後續經濟價值的證據將顯著改善與醫療系統的採購談判。

採用嚴謹的混合方法研究途徑，結合對臨床專家的訪談、監管映射和供應鏈分析，以檢驗決策者的策略見解。

本分析採用混合研究方法，整合了對關鍵相關人員的訪談、醫療設備附加檔、同行評審的臨床文獻，以及對企業資訊披露和臨床註冊資料的結構化研究途徑。重點工作包括與介入性心臟病專家、採購經理和臨床營運主管進行訪談，以了解當代決策者和手術趨勢。這些定性研究結果與醫療設備適應症、手術通訊協定和已發表的療效數據的分析結果進行交叉比對，以確保臨床結論有證據支持。

整合臨床、商業性和營運要求，以明確組織應如何協調投資、證據和供應鏈，從而在溶栓治療領域中取得成功。

總之，以導管為基礎的溶栓療法正處於一個轉折點，醫療設備創新、醫療服務分散化和價值主導型採購在此交匯，有可能重塑市場格局。產品架構與終端用戶需求之間的互動，要求我們制定有針對性的證據和差異化的商業性策略。同時，關稅和各地法規差異等外部壓力正在重塑供應鏈和產品優先級，凸顯了建立具有韌性的製造體系和靈活籌資策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：導管導引溶栓裝置市場：依產品類型分類

  • 點滴導管
    • 持續輸注
    • 脈衝注射
  • 機械導管
    • 吸痰管
    • 理論導管
    • 旋轉導管
  • 超音波輔助導管
    • 增強超音波
    • 標準超音波

第9章：導管導引溶栓裝置市場：依疾病分類

  • 深層靜脈栓塞症
    • 髂股靜脈血栓症
    • 股膕窩深層靜脈栓塞症
  • 肺動脈栓塞
    • 中度風險肺動脈栓塞
    • 高危險肺動脈栓塞
  • 周邊動脈血栓症
    • 急性肢體缺血
  • 透析通路血栓症
  • 靜脈支架或移植血栓症

第10章：導管引導式溶栓裝置市場：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 專科診所
  • 透析中心

第11章：依病患年齡層別分類的導管溶栓裝置市場

  • 兒童患者
  • 成年患者
  • 老年人

第12章：導管導引溶栓裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：導管引導式溶栓裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：導管引導式溶栓裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國導管引導式溶栓裝置市場

第16章：中國導管導引溶栓裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Asahi Intecc Co., Ltd.
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • BTG Limited
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Inari Medical, Inc.
  • iVascular SLU
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Thrombolex, Inc.
Product Code: MRR-1A1A064C03AA

The Catheter-Directed Thrombolysis Devices Market was valued at USD 482.37 million in 2025 and is projected to grow to USD 511.60 million in 2026, with a CAGR of 5.37%, reaching USD 695.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 482.37 million
Estimated Year [2026] USD 511.60 million
Forecast Year [2032] USD 695.82 million
CAGR (%) 5.37%

A clear and authoritative framing of the evolving clinical, operational, and commercial dynamics defining catheter-directed thrombolysis adoption and strategic priorities

Catheter-directed thrombolysis continues to evolve as a pivotal intervention for acute vascular occlusions, driven by advances in device design, imaging integration, and procedural workflows. This executive summary synthesizes the critical clinical, commercial, and regulatory dynamics shaping the field, focusing on device innovation, shifting care settings, and the operational requirements that providers and manufacturers must navigate. Clinicians increasingly favor targeted approaches that maximize thrombus resolution while minimizing systemic fibrinolytic exposure, which reinforces the centrality of device-level performance and delivery precision.

Across interventional suites, the interplay between device efficiency and procedural throughput influences adoption curves. Hospitals and specialty clinics demand predictable performance, while ambulatory surgical centers are exploring same-day treatment models that require streamlined protocols and robust safety profiles. In parallel, health economic pressures are prompting procurement teams to scrutinize total cost of care and downstream outcomes, making clinical evidence and real-world performance critical components of adoption strategies.

Regulatory scrutiny and reimbursement considerations are exerting continual influence on product development and commercialization. Developers must balance speed-to-market with rigorous post-market evidence generation to support both clinician confidence and payer engagement. Consequently, strategic alignment between R&D, clinical affairs, and commercial teams becomes a prerequisite for long-term competitiveness. This introduction frames the subsequent analysis, which delves into structural shifts, tariff-driven supply chain implications, segmentation nuances, regional performance vectors, competitive behavior, and practical recommendations for market leaders.

How integrated imaging, decentralized care pathways, and strategic partnerships are reshaping device design, clinical workflows, and competitive moats in catheter-directed thrombolysis

The landscape of catheter-directed thrombolysis is undergoing transformative shifts that extend well beyond discrete device upgrades to encompass care delivery models, digital integration, and value-based procurement. One major change is the growing convergence of imaging, device control, and procedural analytics. Enhanced integration permits precise targeting of thrombolytic delivery and real-time assessment of reperfusion, which in turn supports shorter procedures and potentially fewer follow-up interventions. As a result, technology roadmaps increasingly prioritize closed-loop procedural support and data capture to inform both clinical decision-making and payer conversations.

Another critical trend is the decentralization of vascular care. Ambulatory settings and specialty clinics are expanding their procedural portfolios, demanding devices that are intuitive, have reduced accessory requirements, and can be deployed with smaller care teams. This operational shift necessitates new training paradigms and redefined value propositions for manufacturers, who must demonstrate ease of use alongside clinical efficacy. Meanwhile, device developers are accelerating modularization and platform strategies so that incremental innovations can be introduced without full-system replacements, thereby preserving installed-base relationships and smoothing upgrade cycles.

Finally, cross-sector partnerships are reshaping competitive dynamics. Collaborations between device OEMs, imaging companies, and digital health firms are enabling bundled solutions that emphasize outcome tracking and procedural optimization. These alliances are creating higher barriers to entry for single-product suppliers and rewarding firms that can offer integrated clinical workflows. Taken together, these transformative shifts require stakeholders to prioritize interoperability, training, and evidence generation to secure long-term relevance.

How tariff-driven supply chain shifts through 2025 are forcing manufacturers to reconfigure production, sourcing, and commercial strategies to protect margin and access

The cumulative impact of recent tariff policies in the United States through 2025 has altered supply chain calculus and strategic sourcing for device manufacturers serving the catheter-directed thrombolysis market. Tariffs have increased the landed cost of certain imported components and finished goods, prompting many suppliers to reassess their sourcing footprints and to accelerate nearshoring or domestic manufacturing investments. Procurement teams now weigh the trade-offs between unit cost, lead-time resilience, and regulatory compliance, often selecting multi-sourcing strategies to mitigate single-origin risk.

In response to tariff-driven cost pressures, manufacturers have pursued process and product-level optimizations to preserve margin while maintaining clinical performance. These adjustments include greater use of local contract manufacturing organizations for final assembly, reengineering of packaging to reduce freight volumetrics, and negotiation of longer-term supplier agreements to stabilize input pricing. Concurrently, some companies have adopted hedging strategies and pricing clauses that pass a portion of increased input costs through to purchasers, while others have absorbed costs temporarily to maintain competitive positioning.

From a market access perspective, tariff effects have influenced device lifecycle decisions, such as prioritizing higher-margin product lines for domestic production and postponing lower-margin variants that are more exposed to import costs. In addition, tariff uncertainty has elevated the importance of scenario planning within commercial strategies, with firms building flexible go-to-market playbooks that can adapt to sudden cost shifts. Ultimately, the tariff environment through 2025 has reinforced the strategic value of supply chain transparency, nimble manufacturing, and close collaboration across procurement, regulatory, and commercial functions to protect access and sustain innovation.

Segment-specific performance imperatives and adoption pathways reveal how product architecture and care settings jointly determine clinical uptake and commercial playbooks

A granular understanding of product and end-user segmentation reveals differentiated performance drivers and adoption barriers across the catheter-directed thrombolysis ecosystem. Based on Product Type, market dynamics diverge between Infusion Catheter variants such as Continuous Infusion and Pulsatile Infusion, Mechanical Catheter subtypes including Aspiration Catheter, Rheolytic Catheter, and Rotational Catheter, and Ultrasound-Assisted Catheter categories split into Enhanced Ultrasound and Standard Ultrasound. Each product class presents unique clinical use-cases and procurement considerations: infusion-based systems emphasize controlled lytic delivery and catheter dwell characteristics; mechanical devices trade off procedural speed and embolic risk for reduced lytic exposure; and ultrasound-enabled platforms promise faster thrombus disruption at the cost of additional system complexity and training demands.

Based on End User, adoption pathways differ across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with each setting imposing distinct requirements on device usability, inventory management, and ancillary services. Hospitals typically demand devices that fit into complex care pathways, offering comprehensive training support, service contracts, and immediate technical escalation. Specialty clinics value targeted performance attributes and streamlined reimbursement support, while ambulatory surgical centers prioritize devices that minimize procedure time, reduce post-procedural monitoring, and support same-day discharge. These differences influence product design priorities and commercial tactics, such as bundled offering development, clinical training programs, and flexible financing structures.

Transitioning from segmentation to execution, manufacturers should align clinical evidence generation and customer engagement with the unique requirements of each product subtype and end-user setting. By mapping clinical workflows to device capabilities and reimbursement pathways, organizations can craft differentiated value narratives and targeted adoption pilots that demonstrably address provider pain points while minimizing operational friction.

How regional regulatory complexity, payer heterogeneity, and capacity expansion shape differentiated market access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on device development priorities, regulatory strategy, and commercial deployment, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each presenting distinct vectors of opportunity and constraint. In the Americas, strong hospital networks, established interventional specialist communities, and relatively rapid adoption of minimally invasive therapies support early uptake of advanced thrombolysis platforms. However, heterogeneity in payer reimbursement policies and the increasing emphasis on value-based contracting require manufacturers to present robust clinical and health economic evidence to secure preferred positioning with large hospital systems.

Europe, Middle East & Africa encompasses a wide spectrum of regulatory regimes and procurement approaches, where centralized reimbursement decisions in some jurisdictions coexist with hospital-level purchasing practices in others. This regional complexity necessitates adaptive market access strategies, such as modular clinical programs that can be calibrated to local evidence requirements and commercial partnerships that extend reimbursement support and clinician training. In contrast, Asia-Pacific is characterized by rapid capacity expansion, an expanding interventionalist workforce, and intense price sensitivity in several markets. Manufacturers seeking traction in APAC often combine tiered pricing models with local training initiatives and selective manufacturing partnerships to meet cost and regulatory demands.

Across all regions, cross-border coordination of clinical evidence, post-market surveillance, and supply chain resilience is critical. Firms that can harmonize global regulatory submissions, while tailoring real-world evidence collection and pricing approaches to regional specifics, are better positioned to scale adoption efficiently and to manage the operational complexity inherent in multi-regional rollouts.

Why successful companies combine platform-level innovation, evidence generation, and integrated services to build durable competitive advantage in thrombolysis therapies

Competitive dynamics among firms active in catheter-directed thrombolysis are increasingly defined by a blend of clinical differentiation, systems-level integration, and strategic partnerships. Leading developers have shifted from offering singular catheter products to providing ecosystem plays that include imaging integration, procedural analytics, and service packages designed to shorten learning curves and improve outcomes. This movement elevates the importance of breadth in clinical data, multi-center real-world evidence, and the capability to support intensive training programs that de-risk adoption for health systems.

Acquisitions and licensing deals are commonplace as companies seek to augment technical portfolios with complementary technologies such as ultrasound energy delivery, advanced infusion control, or thrombectomy modalities. Firms that have invested early in platform architectures gain an advantage because modular upgrades can be introduced with less disruption to existing customers, fostering stickiness and recurring revenue through consumables and service agreements. At the same time, agile smaller companies often drive innovation in niche product features and can influence clinical practice when their solutions demonstrably reduce procedure time or complication rates.

From a go-to-market perspective, successful companies combine clinical and economic narratives. They articulate not only improvements in vessel patency and procedural efficiency but also measurable reductions in length of stay, readmission risk, and adverse event rates. Those that collaborate closely with key opinion leaders to publish outcomes and to design pragmatic training curricula tend to accelerate clinician trust and adoption. To preserve competitive advantage, leading firms are investing in post-market surveillance systems and outcome registries that continually reinforce product value and inform iterative design enhancements.

Practical and prioritized actions for executives to convert technical differentiation into commercial scale through interoperability, resilient supply chains, and targeted evidence generation

Industry leaders should pursue a set of coordinated actions that translate device-level advantages into sustainable commercial outcomes. First, prioritize interoperable product architectures that enable rapid integration with imaging and data systems, thereby creating procedural efficiencies and facilitating outcome measurement. Investing in modular platforms reduces upgrade friction for existing customers and creates recurring revenue opportunities through consumables and service contracts. Second, align clinical affairs, regulatory, and reimbursement teams to develop targeted evidence packages for prioritized segments and regions; evidence that demonstrates both clinical benefit and downstream economic value will materially improve procurement conversations with health systems.

Third, strengthen supply chain resilience through dual sourcing, regional manufacturing partnerships, and transparent inventory analytics to mitigate tariff and logistics risks. This reduces vulnerability to input-cost shocks and supports reliable customer delivery timelines. Fourth, deploy differentiated commercial models that reflect end-user needs-hospitals require comprehensive training and service support, specialty clinics value streamlined deployment and cost predictability, and ambulatory surgical centers seek devices that enable same-day pathways. Tailored pricing, financing, and training packages will accelerate adoption across these settings.

Finally, commit to collaborative partnerships with clinical centers for real-world evidence generation and procedural optimization. These collaborations should target clinical outcome registries and pragmatic trials that inform continuous product improvements and strengthen payer engagement. By executing on these priorities with discipline, industry leaders can convert technological innovation into measurable improvements in patient outcomes and durable market positions.

A rigorous mixed-methods research approach combining clinical expert interviews, regulatory mapping, and supply chain analysis to validate strategic insights for decision-makers

This analysis is grounded in a mixed-methods research approach that synthesizes primary stakeholder interviews, device labeling and regulatory documentation, peer-reviewed clinical literature, and a structured review of company disclosures and clinical registries. Primary engagement included interviews with interventional specialists, procurement leaders, and clinical affairs executives to capture contemporary decision drivers and procedural trends. These qualitative insights were triangulated with an analysis of device indications, procedural protocols, and published outcome data to ensure clinical assertions are supported by evidence.

Supplementing qualitative inputs, the methodology incorporated a structured assessment of supply chain footprints, tariff exposures, and manufacturing options based on publicly available trade and customs data. Regional regulatory frameworks were mapped against device classification and pre-market pathways to identify typical requirements and potential accelerators for market entry. Additionally, competitive behavior was examined through disclosures, patent filings, and partnership announcements to identify strategic patterns such as platform expansion, vertical integration, and service-oriented monetization.

Throughout the research process, rigorous validation practices were applied. Key findings and interpretations were subjected to expert review and iterative refinement with clinical and commercial advisors. Where appropriate, sensitivity to regional heterogeneity and clinical practice variation was maintained to avoid overgeneralization. This methodological rigor supports both the credibility of the insights presented and their applicability to practical strategy development.

A synthesis of clinical, commercial, and operational imperatives that clarifies how organizations should align investment, evidence, and supply chains to win in thrombolysis

In conclusion, catheter-directed thrombolysis is at an inflection point where device innovation, care-setting decentralization, and value-driven procurement intersect to redefine market trajectories. The interplay between product architecture and end-user requirements necessitates focused evidence generation and differentiated commercial approaches. Meanwhile, external pressures such as tariffs and regional regulatory diversity are reshaping supply chains and product prioritization, underscoring the need for resilient manufacturing and flexible sourcing strategies.

Manufacturers that invest in interoperable platforms, build compelling health economic narratives, and pursue pragmatic partnerships with clinical centers will be best positioned to capture long-term value. Likewise, commercial leaders must tailor propositions to the distinct operational realities of hospitals, specialty clinics, and ambulatory surgical centers, while maintaining the agility to adapt to regional nuances. Ultimately, success will rest on the ability to translate technical improvements into demonstrable clinical outcomes and measurable reductions in total cost of care, thereby answering the practical questions that payers and providers pose during procurement.

This executive summary is intended to inform strategic planning, guide prioritization of R&D and market access investments, and support alignment across clinical, regulatory, and commercial functions so that organizations can confidently navigate the evolving landscape and accelerate adoption of best-in-class thrombolysis solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Catheter-Directed Thrombolysis Devices Market, by Product Type

  • 8.1. Infusion Catheter
    • 8.1.1. Continuous Infusion
    • 8.1.2. Pulsatile Infusion
  • 8.2. Mechanical Catheter
    • 8.2.1. Aspiration Catheter
    • 8.2.2. Rheolytic Catheter
    • 8.2.3. Rotational Catheter
  • 8.3. Ultrasound-Assisted Catheter
    • 8.3.1. Enhanced Ultrasound
    • 8.3.2. Standard Ultrasound

9. Catheter-Directed Thrombolysis Devices Market, by Clinical Indication

  • 9.1. Deep Vein Thrombosis
    • 9.1.1. Iliofemoral Deep Vein Thrombosis
    • 9.1.2. Femoro-Popliteal Deep Vein Thrombosis
  • 9.2. Pulmonary Embolism
    • 9.2.1. Intermediate-Risk Pulmonary Embolism
    • 9.2.2. High-Risk Pulmonary Embolism
  • 9.3. Peripheral Arterial Thrombosis
    • 9.3.1. Acute Limb Ischemia
  • 9.4. Dialysis Access Thrombosis
  • 9.5. Venous Stent Or Graft Thrombosis

10. Catheter-Directed Thrombolysis Devices Market, by End User

  • 10.1. Hospitals
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Specialty Clinics
  • 10.4. Dialysis Centers

11. Catheter-Directed Thrombolysis Devices Market, by Patient Age Group

  • 11.1. Pediatric Patients
  • 11.2. Adult Patients
  • 11.3. Geriatric Patients

12. Catheter-Directed Thrombolysis Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Catheter-Directed Thrombolysis Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Catheter-Directed Thrombolysis Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Catheter-Directed Thrombolysis Devices Market

16. China Catheter-Directed Thrombolysis Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AngioDynamics, Inc.
  • 17.7. Asahi Intecc Co., Ltd.
  • 17.8. Bayer AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Boston Scientific Corporation
  • 17.11. BTG Limited
  • 17.12. Cardinal Health, Inc.
  • 17.13. Cook Medical LLC
  • 17.14. Inari Medical, Inc.
  • 17.15. iVascular S.L.U.
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Koninklijke Philips N.V.
  • 17.18. Medtronic plc
  • 17.19. Merit Medical Systems, Inc.
  • 17.20. Penumbra, Inc.
  • 17.21. Stryker Corporation
  • 17.22. Teleflex Incorporated
  • 17.23. Terumo Corporation
  • 17.24. Thrombolex, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ILIOFEMORAL DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ILIOFEMORAL DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ILIOFEMORAL DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY FEMORO-POPLITEAL DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY FEMORO-POPLITEAL DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY FEMORO-POPLITEAL DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INTERMEDIATE-RISK PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INTERMEDIATE-RISK PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INTERMEDIATE-RISK PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HIGH-RISK PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HIGH-RISK PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HIGH-RISK PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ACUTE LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ACUTE LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ACUTE LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS ACCESS THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS ACCESS THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS ACCESS THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY VENOUS STENT OR GRAFT THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY VENOUS STENT OR GRAFT THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY VENOUS STENT OR GRAFT THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROM